Immune Checkpoint Inhibition: The Rising Star in Oncology Therapeutics (Merck Animal Health) - Industry Lunch

It’s time to learn about a new modality for treating cancer. Immunotherapy has been taking the human oncologic world by storm, and in particular, the use of immune checkpoint inhibitors has remarkable potential to provide complete responses with significant duration for some patients. The first commercially available checkpoint inhibitor in veterinary medicine is gilvetmab: an anti-PD-1 monoclonal antibody conditionally licensed for use in dogs with mast cell tumor stages I, II, and III and dogs with melanoma stages II and III. In this session, attendees will gain a familiarity with immune checkpoint inhibitors, learn how they work, how to talk to owners about this therapy, and how you can gain the greatest benefit for your patients with immune checkpoint inhibition. Presented by: Merck Animal Health